Evaluation of CI-564, A 1:1 mixture of cycloguanil pamoate (CI-501) and 4,4'-diacetylaminodiphenylsulfone (CI-556), against multiresistant falciparum malarias.
D000962:Antimalarials / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D008297:Male; D010963:Plasmodium falciparum / Q000187:drug effects; D013450:Sulfones / Q000627:therapeutic use*; D014227:Triazines / Q000627:therapeutic use*
D000962:Antimalarials; D013450:Sulfones; D014227:Triazines